Suchergebnisse - "Lung Neoplasms mortality"
-
1
Autoren: et al.
Quelle: N Engl J Med
The New England journal of medicine, vol. 392, no. 16, pp. 1594-1608Schlagwörter: Male, Lung Neoplasms, Middle Aged, Article, Monocytes, Dioxygenases, DNA-Binding Proteins, Mice, Observational Studies as Topic, Cell Movement, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Mutation, Tumor Microenvironment, Animals, Humans, Female, Prospective Studies, Clonal Hematopoiesis, Neoplasm Recurrence, Local, Aged, Carcinoma, Non-Small-Cell Lung/genetics, Carcinoma, Non-Small-Cell Lung/immunology, Carcinoma, Non-Small-Cell Lung/mortality, Carcinoma, Non-Small-Cell Lung/pathology, Clonal Hematopoiesis/genetics, Clonal Hematopoiesis/immunology, Dioxygenases/genetics, DNA-Binding Proteins/genetics, Lung Neoplasms/genetics, Lung Neoplasms/mortality, Lung Neoplasms/pathology, Neoplasm Recurrence, Local/epidemiology, Neoplasm Recurrence, Local/genetics, Neoplasm Recurrence, Local/pathology, Tumor Microenvironment/immunology, Monocytes/immunology, Monocytes/pathology, Cell Movement/genetics, Cell Movement/immunology, Neoplasm Transplantation
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40267425
https://ora.ox.ac.uk/objects/uuid:e20d5bce-3d87-4ac2-9e89-b887ca4cc72b
https://doi.org/10.1056/nejmoa2413361
https://serval.unil.ch/notice/serval:BIB_435B0ABCF518
https://serval.unil.ch/resource/serval:BIB_435B0ABCF518.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_435B0ABCF5187 -
2
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Digital.CSIC. Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Journal of thoracic oncology, vol. 20, no. 1, pp. 94-108Schlagwörter: PD-L1, Nivolumab, Non–small cell lung cancer, Humans, Nivolumab/pharmacology, Nivolumab/therapeutic use, Nivolumab/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/mortality, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Lung Neoplasms/mortality, Lung Neoplasms/metabolism, Ipilimumab/pharmacology, Ipilimumab/therapeutic use, Ipilimumab/administration & dosage, Male, Female, Middle Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, B7-H1 Antigen/metabolism, Aged, Adult, Survival Rate, Aged, 80 and over, Follow-Up Studies, Immunotherapy, Ipilimumab
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39369790
http://hdl.handle.net/10261/390933
https://api.elsevier.com/content/abstract/scopus_id/85208360083
https://serval.unil.ch/resource/serval:BIB_89D370D6F09D.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_89D370D6F09D
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_89D370D6F09D7 -
3
Autoren: et al.
Quelle: Journal of thoracic oncology, vol. 20, no. 1, pp. 76-93
Schlagwörter: Male, Adult, Humans, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/mortality, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Lung Neoplasms/mortality, Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antibodies, Monoclonal/therapeutic use, Female, Middle Aged, Aged, Survival Rate, Follow-Up Studies, Neoplasm Metastasis, Durvalumab, Five-year overall survival, Metastatic NSCLC, POSEIDON, Tremelimumab, Lung Neoplasms, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols
Dateibeschreibung: application/pdf
-
4
Autoren: et al.
Quelle: Journal of Cachexia, Sarcopenia and Muscle. 16
Schlagwörter: Male, Sarcopenia, T-Lymphocytes, skeletal muscle mass, Middle Aged, survival, lung cancer, Cytotoxic/immunology, Skeletal/pathology, Body Composition, Humans, Muscle, Female, Lymphocytes, Tumor-Infiltrating, Lung Neoplasms/mortality pathology complications immunology, TILs, cytotoxic T cell, Aged
-
5
Autoren: et al.
Quelle: J Neurooncol
Schlagwörter: 0301 basic medicine, 03 medical and health sciences, 0302 clinical medicine, Research, Disease Progression [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], TTF-1, Adenocarcinoma of Lung/surgery [MeSH], Survival, Male [MeSH], Brain Neoplasms/mortality [MeSH], Brain Metastasis, Ki67, Edema volume, LUAD, Female [MeSH], Lung Neoplasms/mortality [MeSH], Follow-Up Studies [MeSH], Brain Neoplasms/secondary [MeSH], Adult [MeSH], Humans [MeSH], Tumor volume, Retrospective Studies [MeSH], Middle Aged [MeSH], Adenocarcinoma of Lung/metabolism [MeSH], Survival Rate [MeSH], Biomarkers, Tumor/metabolism [MeSH], Adenocarcinoma of Lung/mortality [MeSH], Prognosis [MeSH], Lung Neoplasms/pathology [MeSH], Lung Neoplasms/metabolism [MeSH], Adenocarcinoma of Lung/pathology [MeSH], Brain Neoplasms/metabolism [MeSH], Thyroid Nuclear Factor 1/metabolism [MeSH]
-
6
Autoren: et al.
Quelle: Acta Oncol
Acta Oncologica, Vol 63, Iss 1 (2024)
Sørensen, J B, Baas, P, Szépligeti, S K, Pedersen, A B, Johnsen, S P, Carroll, R, Schoemaker, M J, Rault, C, Daumont, M J & Ehrenstein, V 2024, 'Patient characteristics, treatment patterns, and survival outcomes for patients with malignant pleural mesothelioma in Denmark between 2011 and 2018: a nationwide population-based cohort study', Acta Oncologica, vol. 63, pp. 649-657. https://doi.org/10.2340/1651-226X.2024.34802
Sørensen, J B, Baas, P, Szépligeti, S K, Pedersen, A B, Johnsen, S P, Carroll, R, Schoemaker, M J, Rault, C, Daumont, M J & Ehrenstein, V 2024, 'Patient characteristics, treatment patterns, and survival outcomes for patients with malignant pleural mesothelioma in Denmark between 2011 and 2018 : a nationwide population-based cohort study', Acta oncologica (Stockholm, Sweden), vol. 63, pp. 649-657. https://doi.org/10.2340/1651-226X.2024.34802Schlagwörter: Male, Lung Neoplasms, Epidemiology, Denmark, Pleural Neoplasms, Cohort Studies, malignant pleural mesothelioma, Humans, Registries, RC254-282, Aged, Aged, 80 and over, Mesothelioma, Malignant, Registries/statistics & numerical data, registries, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Lung Neoplasms/mortality, Denmark/epidemiology, 3. Good health, Survival Rate, Pleural Neoplasms/mortality, Mesothelioma, Malignant/therapy, epidemiology, Original Article, Female, Cohort study
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39114950
https://doaj.org/article/12feb6552e244e149a6d6c1e2c4ce6c3
https://vbn.aau.dk/da/publications/c2b024cd-99d6-4235-83de-4df377c06f65
http://www.scopus.com/inward/record.url?scp=85200939292&partnerID=8YFLogxK
https://vbn.aau.dk/ws/files/740602972/S_rensen_et_al._2024_._Patient_characteristics_treatment_patterns_and_survival_outcomes_for_patients_with_malignant_pleural_mesothelioma_in_Denmark_between_2011_and_2018_-_a_nationwide_population-based_cohort_study.pdf
https://doi.org/10.2340/1651-226X.2024.34802
https://hdl.handle.net/1887/4195217
http://www.scopus.com/inward/record.url?scp=85200939292&partnerID=8YFLogxK
https://pure.au.dk/portal/en/publications/9276554e-c074-45a0-bf38-6b47c6dfa6ec
https://doi.org/10.2340/1651-226X.2024.34802 -
7
Autoren: et al.
Quelle: Thorac Cancer
Thoracic Cancer, Vol 15, Iss 17, Pp 1350-1356 (2024)Schlagwörter: Male, Adult, Lung Neoplasms, small-cell lung cancer (SCLC), Small Cell Lung Carcinoma/immunology, 80 and over, paraneoplastic neurological syndromes (PNS), Humans, RC254-282, Autoantibodies, Aged, Retrospective Studies, Aged, 80 and over, Neurons, Neurons/pathology, anti‐neuronal antibodies, anti-neuronal antibodies, autoimmunity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Original Articles, Middle Aged, Lung Neoplasms/mortality, Prognosis, Small Cell Lung Carcinoma, 3. Good health, small‐cell lung cancer (SCLC), Female, Autoantibodies/blood
-
8
Autoren: et al.
Quelle: Strahlenther Onkol
Schlagwörter: Male, Mesothelioma, Aged, 80 and over, Adult, Mesothelioma/mortality [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Progression-Free Survival [MeSH], Mesothelioma/radiotherapy [MeSH], Trimodal therapy, Organ Sparing Treatments/methods [MeSH], Mesothelioma, Malignant/radiotherapy [MeSH], Original Article, Neoplasm Staging [MeSH], Survival, Male [MeSH], Pleural Neoplasms/mortality [MeSH], Adjuvant radiotherapy, Combined Modality Therapy [MeSH], Radiotherapy, Intensity-Modulated/methods [MeSH], Female [MeSH], Lung Neoplasms/mortality [MeSH], Intensity-modulated radiotherapy, Adult [MeSH], Lung Neoplasms/radiotherapy [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Pleural Neoplasms/radiotherapy [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Lung Neoplasms/surgery [MeSH], Mesothelioma, Malignant/surgery [MeSH], Chemotherapy, Adjuvant [MeSH], Pleural Neoplasms/surgery [MeSH], Pneumonectomy [MeSH], Lung Neoplasms/pathology [MeSH], Mesothelioma/surgery [MeSH], Local tumor control, Lung Neoplasms, Pleural Neoplasms, Mesothelioma, Malignant, Middle Aged, Combined Modality Therapy, Progression-Free Survival, 3. Good health, Treatment Outcome, Chemotherapy, Adjuvant, Humans, Female, Radiotherapy, Intensity-Modulated, Pneumonectomy, Organ Sparing Treatments, Aged, Retrospective Studies, Neoplasm Staging
-
9
Autoren: et al.
Quelle: Strahlenther Onkol
Schlagwörter: Male, Aged, 80 and over, Adult, Lung Neoplasms, Aged, 80 and over [MeSH], Aged [MeSH], Metastasis, Original Article, Neoplasm Staging [MeSH], Carcinoma, Non-Small-Cell Lung/mortality [MeSH], Male [MeSH], Brain Neoplasms/mortality [MeSH], Thoracic Radiotherapy, Carcinoma, Non-Small-Cell Lung/pathology [MeSH], Female [MeSH], Outcome, Lung Neoplasms/mortality [MeSH], Brain Neoplasms/secondary [MeSH], Lung Neoplasms/therapy [MeSH], Adult [MeSH], Lung Cancer, Humans [MeSH], Neoplasm Metastasis [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Lung Neoplasms/pathology [MeSH], Immune Checkpoint Inhibition, Carcinoma, Non-Small-Cell Lung/therapy [MeSH], Chemoradiotherapy [MeSH], Brain Neoplasms/therapy [MeSH], Brain Neoplasms, Chemoradiotherapy, Middle Aged, 3. Good health, Carcinoma, Non-Small-Cell Lung, Humans, Female, Neoplasm Metastasis, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Neoplasm Staging
-
10
Autoren: et al.
Weitere Verfasser: et al.
Quelle: ISSN: 2162-4011.
Schlagwörter: benzodiazepines CONTACT Edoardo Pasolli, ACBP acyl CoA binding protein NSCLC lung adenocarcinoma lung squamous carcinoma psychotropic agents benzodiazepines CONTACT Edoardo Pasolli, ACBP, acyl CoA binding protein, NSCLC, lung adenocarcinoma, lung squamous carcinoma, psychotropic agents, MESH: Adult, MESH: Aged, MESH: Carcinoma, Non-Small-Cell Lung* / pathology, MESH: Female, MESH: France / epidemiology, MESH: Humans, MESH: Immune Checkpoint Inhibitors / therapeutic use, MESH: Immunotherapy* / methods, MESH: Lung Neoplasms* / drug therapy, MESH: Lung Neoplasms* / mortality, MESH: Lung Neoplasms* / pathology, MESH: Male, 80 and over, MESH: Middle Aged, MESH: Programmed Cell Death 1 Receptor / antagonists & inhibitors, MESH: Retrospective Studies, MESH: Treatment Outcome, MESH: Antibodies, Monoclonal, Humanized* / therapeutic use, MESH: Antineoplastic Agents
Relation: info:eu-repo/semantics/altIdentifier/pmid/40613596; info:eu-repo/grantAgreement//101052444/EU/Immunogenic cell death (ICD) in the cancer-immune dialogue/ICD-Cancer; PUBMED: 40613596; PUBMEDCENTRAL: PMC12233713
-
11
Autoren: et al.
Quelle: Journal for immunotherapy of cancer, vol. 13, no. 2
Schlagwörter: Humans, Carcinoma, Non-Small-Cell Lung/drug therapy, Non-Small-Cell Lung/mortality, Non-Small-Cell Lung/pathology, Male, Antibodies, Monoclonal, Humanized/therapeutic use, Female, Lung Neoplasms/drug therapy, Lung Neoplasms/mortality, Lung Neoplasms/pathology, Aged, Middle Aged, Registries, B7-H1 Antigen/antagonists & inhibitors, B7-H1 Antigen/metabolism, Antineoplastic Agents, Immunological/therapeutic use, Adult, 80 and over, Immune Checkpoint Inhibitor, Immunotherapy, Lung Cancer
Dateibeschreibung: application/pdf
Relation: info:eu-repo/semantics/altIdentifier/pmid/39904562; info:eu-repo/semantics/altIdentifier/eissn/2051-1426; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_32FF4EB5874F2; https://serval.unil.ch/notice/serval:BIB_32FF4EB5874F; https://serval.unil.ch/resource/serval:BIB_32FF4EB5874F.P001/REF.pdf
-
12
Autoren: et al.
Quelle: ISSN: 2051-1426 ; Journal for immunotherapy of cancer, vol. 13, no. 2 (2025) e010674.
Schlagwörter: info:eu-repo/classification/ddc/616, Immune Checkpoint Inhibitor, Immunotherapy, Lung Cancer, Humans, Carcinoma, Non-Small-Cell Lung / drug therapy, Non-Small-Cell Lung / mortality, Non-Small-Cell Lung / pathology, Male, Antibodies, Monoclonal, Humanized / therapeutic use, Female, Lung Neoplasms / drug therapy, Lung Neoplasms / mortality, Lung Neoplasms / pathology, Aged, Middle Aged, Registries, B7-H1 Antigen / antagonists & inhibitors, B7-H1 Antigen / metabolism, Antineoplastic Agents, Immunological / therapeutic use, Adult, 80 and over
Relation: info:eu-repo/semantics/altIdentifier/pmid/39904562; unige:183983
Verfügbarkeit: https://archive-ouverte.unige.ch/unige:183983
-
13
Autoren: et al.
Quelle: Cancer Imaging
Cancer Imaging, Vol 24, Iss 1, Pp 1-13 (2024)Schlagwörter: Adult, Male, Lung Neoplasms, PET/CT, R895-920, NSCLC, TNM, Medical physics. Medical radiology. Nuclear medicine, 03 medical and health sciences, 0302 clinical medicine, Fluorodeoxyglucose F18, Carcinoma, Non-Small-Cell Lung, Positron Emission Tomography Computed Tomography, Humans, Carcinoma, Non-Small-Cell Lung/metabolism [MeSH], Carcinoma, Non-Small-Cell Lung/diagnostic imaging [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Radiopharmaceuticals [MeSH], Prognosis, Fluorodeoxyglucose F18 [MeSH], Neoplasm Staging [MeSH], Carcinoma, Non-Small-Cell Lung/mortality [MeSH], Male [MeSH], Positron Emission Tomography Computed Tomography/methods [MeSH], Tumor Burden [MeSH], Carcinoma, Non-Small-Cell Lung/pathology [MeSH], Female [MeSH], Lung Neoplasms/diagnostic imaging [MeSH], Lung Neoplasms/mortality [MeSH], Lung Neoplasms/therapy [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Metabolic tumor volume, Research, Prognosis [MeSH], Lung Neoplasms/pathology [MeSH], Lung cancer, Carcinoma, Non-Small-Cell Lung/therapy [MeSH], Chemoradiotherapy [MeSH], RC254-282, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Chemoradiotherapy, Middle Aged, Tumor Burden, Female, Radiopharmaceuticals
Dateibeschreibung: pdf
-
14
Autoren:
Quelle: J Cancer Res Clin Oncol
Schlagwörter: Male, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung/metabolism [MeSH], Aged [MeSH], Progression-Free Survival [MeSH], TTF-1 expression, NSCLC, Immunotherapy/methods [MeSH], Carcinoma, Non-Small-Cell Lung/mortality [MeSH], Male [MeSH], Transcription Factors/metabolism [MeSH], Carcinoma, Non-Small-Cell Lung/pathology [MeSH], Female [MeSH], Lung Neoplasms/mortality [MeSH], Lung Neoplasms/therapy [MeSH], DNA-Binding Proteins [MeSH], Humans [MeSH], Prognostic factor for therapy, Retrospective Studies [MeSH], Middle Aged [MeSH], Chemo-/immunotherapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Biomarkers, Tumor/metabolism [MeSH], Research, Immunotherapy, Lung Neoplasms/pathology [MeSH], Lung Neoplasms/metabolism [MeSH], Carcinoma, Non-Small-Cell Lung/drug therapy [MeSH], Carcinoma, Non-Small-Cell Lung/therapy [MeSH], Lung Neoplasms/drug therapy [MeSH], Thyroid Nuclear Factor 1/metabolism [MeSH], Thyroid Nuclear Factor 1, Middle Aged, Progression-Free Survival, DNA-Binding Proteins, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Female, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Transcription Factors
-
15
Autoren: et al.
Quelle: ESMO Open
ESMO open, vol. 10, no. 5, pp. 105058Schlagwörter: Humans, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/genetics, Carcinoma, Non-Small-Cell Lung/mortality, Carcinoma, Non-Small-Cell Lung/pathology, Lung Neoplasms/drug therapy, Lung Neoplasms/genetics, Lung Neoplasms/pathology, Lung Neoplasms/mortality, Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/pharmacology, Male, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Middle Aged, Mutation, Aged, Antibodies, Monoclonal/therapeutic use, Adult, Treatment Outcome, POSEIDON, durvalumab, non-small-cell lung cancer, tremelimumab, tumor mutational burden, Original Article
Dateibeschreibung: application/pdf
-
16
Autoren: et al.
Quelle: Mol Cancer
Molecular Cancer, Vol 23, Iss 1, Pp 1-17 (2024)Schlagwörter: PD-L1, Male, Adult, 0301 basic medicine, Medical Sciences, Lung Neoplasms, Bioinformatics, Antibodies, Monoclonal, Humanized, Antibodies, Biomedical Informatics, 03 medical and health sciences, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Medical Specialties, Medicine and Health Sciences, Biomarkers, Tumor, Humans, Humanized, Biomarkers, CTLA-4, Aged [MeSH], Antibodies, Monoclonal/therapeutic use [MeSH], T-cell inflamed signature, Lung Neoplasms/genetics [MeSH], Small Cell Lung Carcinoma/mortality [MeSH], Small-cell lung cancer, Neoplasm Staging [MeSH], Immunotherapy/methods [MeSH], SCLC subtypes, Small Cell Lung Carcinoma/drug therapy [MeSH], Male [MeSH], Small Cell Lung Carcinoma/genetics [MeSH], Lung Neoplasms/immunology [MeSH], Small Cell Lung Carcinoma/pathology [MeSH], Biomarkers, Tumor [MeSH], Molecular subtyping, Female [MeSH], Lung Neoplasms/mortality [MeSH], Lung Neoplasms/therapy [MeSH], Adult [MeSH], Humans [MeSH], Small Cell Lung Carcinoma/metabolism [MeSH], Treatment Outcome [MeSH], Gene expression profiling, Middle Aged [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Small Cell Lung Carcinoma/therapy [MeSH], Antigen presentation machinery, Research, Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Prognosis [MeSH], Lung Neoplasms/pathology [MeSH], Lung Neoplasms/metabolism [MeSH], Small Cell Lung Carcinoma/immunology [MeSH], Lung Neoplasms/drug therapy [MeSH], RC254-282, Aged, Neoplasm Staging, 0303 health sciences, Tumor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Antibodies, Monoclonal, Middle Aged, Prognosis, Small Cell Lung Carcinoma, 3. Good health, Treatment Outcome, Oncology, Female, Immunotherapy
Dateibeschreibung: application/pdf
-
17
Autoren: et al.
Quelle: World J Surg Oncol
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-12 (2024)Schlagwörter: Male, Adult, Lung Neoplasms, RD1-811, Databases, Factual, Matched-Pair Analysis, Pulmonary Surgical Procedures, Young Adult, Postoperative Complications, Carcinoma, Non-Small-Cell Lung, Humans, Prospective Studies, Hospital Mortality, RC254-282, Aged, Aged, 80 and over, 2. Zero hunger, Research, Age Factors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Length of Stay, ddc, 3. Good health, Treatment Outcome, Functional Status, Surgery, Female, Carcinoma, Squamous Cell/mortality [MeSH], Length of Stay/statistics, Age Factors [MeSH], Pneumonectomy/adverse effects [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Postoperative Complications/mortality [MeSH], Postoperative Complications/epidemiology [MeSH], Risk Factors [MeSH], Neoplasm Staging [MeSH], Carcinoma, Non-Small-Cell Lung/mortality [MeSH], Male [MeSH], Carcinoma, Squamous Cell/surgery [MeSH], Carcinoma, Squamous Cell/pathology [MeSH], Pneumonectomy/mortality [MeSH], Carcinoma, Non-Small-Cell Lung/pathology [MeSH], Female [MeSH], Lung Neoplasms/mortality [MeSH], Follow-Up Studies [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Lung Neoplasms/surgery [MeSH], Carcinoma, Non-Small-Cell Lung/surgery [MeSH], Survival Rate [MeSH], Morbidity [MeSH], Matched-Pair Analysis [MeSH], Prognosis [MeSH], Lung Neoplasms/pathology [MeSH]
Dateibeschreibung: application/pdf
-
18
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Anticancer Research. 42:1615-1622
Schlagwörter: Afatinib / adverse effects, Male, Lung Neoplasms, Time Factors, Mutation, afatinib, Lung Neoplasms / mortality, Tumor / antagonists & inhibitors, 0302 clinical medicine, Lung neoplasms, Carcinoma, Non-Small-Cell Lung, Afatinib / therapeutic use, 80 and over, Aged, 80 and over, Exons, Middle Aged, ErbB Receptors / antagonists & inhibitors, 3. Good health, Non-Small-Cell Lung / mortality, ErbB Receptors, Treatment Outcome, Female, Non-Small-Cell Lung / pathology, ErbB Receptors / genetics, Adult, Seoul, Lung Neoplasms / pathology, Lung Neoplasms / drug therapy, Antineoplastic Agents, Antineoplastic Agents / therapeutic use, Afatinib, Protein Kinase Inhibitors / therapeutic use, 03 medical and health sciences, Biomarkers, Tumor, Tumor / genetics, Humans, Non-Small-Cell Lung / genetics, Protein Kinase Inhibitors, Non-Small-Cell Lung / drug therapy, Protein Kinase Inhibitors / adverse effects, Aged, Retrospective Studies, Lung Neoplasms / genetics, Antineoplastic Agents / adverse effects, Carcinoma, prognosis, epidermal growth factor receptor, Biomarkers
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/35220259
-
19
Autoren: et al.
Quelle: ESMO open, vol. 9, no. 6, pp. 103464
Schlagwörter: Humans, Carcinoma, Non-Small-Cell Lung/mortality, Non-Small-Cell Lung/pathology, Non-Small-Cell Lung/therapy, Non-Small-Cell Lung/drug therapy, Female, Male, Lung Neoplasms/mortality, Lung Neoplasms/therapy, Lung Neoplasms/pathology, Lung Neoplasms/drug therapy, Middle Aged, Retrospective Studies, Aged, Chemoradiotherapy/methods, Antibodies, Monoclonal/therapeutic use, Antineoplastic Agents, Immunological/therapeutic use, Immunological/pharmacology, Adult, Neoplasm Staging, 80 and over, PD-L1, durvalumab, immunotherapy, locally advanced NSCLC, real-world evidence
Dateibeschreibung: application/pdf
Relation: info:eu-repo/semantics/altIdentifier/pmid/38833971; info:eu-repo/semantics/altIdentifier/eissn/2059-7029; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_8BA41A1F1CC31; https://serval.unil.ch/notice/serval:BIB_8BA41A1F1CC3; https://serval.unil.ch/resource/serval:BIB_8BA41A1F1CC3.P001/REF.pdf
-
20
Autoren: et al.
Quelle: Modern pathology, vol. 37, no. 10, pp. 100571
Schlagwörter: Humans, Observer Variation, Female, Male, Lung Neoplasms/pathology, Lung Neoplasms/surgery, Lung Neoplasms/mortality, Aged, Retrospective Studies, Middle Aged, Carcinoma, Squamous Cell/pathology, Squamous Cell/surgery, Squamous Cell/mortality, Biopsy, Neoplasm Grading, 80 and over, interobserver variability, lung cancer, non–small cell lung carcinoma, preoperative, squamous cell carcinoma, tumor budding
Dateibeschreibung: application/pdf
Relation: info:eu-repo/semantics/altIdentifier/pmid/39038789; info:eu-repo/semantics/altIdentifier/eissn/1530-0285; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B6BDDE9C12179; https://serval.unil.ch/notice/serval:BIB_B6BDDE9C1217; https://serval.unil.ch/resource/serval:BIB_B6BDDE9C1217.P001/REF.pdf
Full Text Finder 
Nájsť tento článok vo Web of Science 
Full Text